PDF(Pubmed)
Abstract：
UNASSIGNED: Liposomal amphotericin use is limited in developing countries due to its extremely high cost and availability. Therefore, the study aimed to evaluate deoxycholate amphotericin B\'s utility and adverse effect profile in patients with mucormycosis.
UNASSIGNED: This retrospective cohort study from 2019 to 2021 included patients with proven mucormycosis who received deoxycholate amphotericin B for more than or equal to five days and had at least three creatinine values on treatment. Baseline demographic details, risk factors and treatment details of all the patients were recorded. In addition, the details of treatment-related adverse effects and outcomes were ascertained.
UNASSIGNED: Of the 57 included patients, a history of diabetes, COVID-19 and steroid use was present in 49 (86%), 43 (75.4%) and 33 (57.9%) patients, respectively. Isolated rhino-orbital mucormycosis was the most common presentation (n=49, 86%). The median time of follow-up was 48 (30.5-90) days. A total of 8 (14%) patients died during the hospital stay. The median duration of amphotericin treatment was 21 (14-40) days. Thirty-nine patients (68.4%) developed hypokalaemia on treatment, while 27 (47.4%) patients developed hypomagnesaemia. A total of 34 (59.6%) patients developed AKI on treatment. The median day of development of AKI was 6 (4-10) days. The median baseline, highest and final creatinine values were 0.78 (0.59-0.94) mg/dl, 1.27 (0.89-2.16) mg/dl and 0.93 (0.74-1.59) mg/ dl respectively. The median percentage change from baseline to highest value and last follow-up value was 45% (0.43%-161%) and 25% (-4.8%-90.1%) respectively. The final creatinine was less than 150% of the baseline in 36 (63.2%) patients.
UNASSIGNED: Deoxycholate amphotericin is an acceptable alternative for treating mucormycosis in resource-constrained settings.
UNASSIGNED: This retrospective cohort study from 2019 to 2021 included patients with proven mucormycosis who received deoxycholate amphotericin B for more than or equal to five days and had at least three creatinine values on treatment. Baseline demographic details, risk factors and treatment details of all the patients were recorded. In addition, the details of treatment-related adverse effects and outcomes were ascertained.
UNASSIGNED: Of the 57 included patients, a history of diabetes, COVID-19 and steroid use was present in 49 (86%), 43 (75.4%) and 33 (57.9%) patients, respectively. Isolated rhino-orbital mucormycosis was the most common presentation (n=49, 86%). The median time of follow-up was 48 (30.5-90) days. A total of 8 (14%) patients died during the hospital stay. The median duration of amphotericin treatment was 21 (14-40) days. Thirty-nine patients (68.4%) developed hypokalaemia on treatment, while 27 (47.4%) patients developed hypomagnesaemia. A total of 34 (59.6%) patients developed AKI on treatment. The median day of development of AKI was 6 (4-10) days. The median baseline, highest and final creatinine values were 0.78 (0.59-0.94) mg/dl, 1.27 (0.89-2.16) mg/dl and 0.93 (0.74-1.59) mg/ dl respectively. The median percentage change from baseline to highest value and last follow-up value was 45% (0.43%-161%) and 25% (-4.8%-90.1%) respectively. The final creatinine was less than 150% of the baseline in 36 (63.2%) patients.
UNASSIGNED: Deoxycholate amphotericin is an acceptable alternative for treating mucormycosis in resource-constrained settings.
摘要：
UNASSIGNED：脂质体两性霉素在发展中国家的使用有限，因为它的成本和可用性极高。因此,本研究旨在评估脱氧胆酸两性霉素B在毛霉菌病患者中的效用和不良反应情况.
UNASSIGNED：这项从2019年至2021年的回顾性队列研究包括确诊的毛霉菌病患者，接受脱氧胆酸两性霉素B治疗超过或等于五天，并且在治疗中至少有三个肌酐值。基线人口统计详细信息，记录所有患者的危险因素和治疗细节.此外,我们确定了治疗相关不良反应和结局的详情.
未经批准：在纳入的57名患者中，有糖尿病史,COVID-19和类固醇的使用有49例（86%），43例（75.4%）和33例（57.9%）患者，分别。孤立的鼻-眶毛霉菌病是最常见的表现（n=49，86％）。中位随访时间为48（30.5-90）天。共有8名(14%)患者在住院期间死亡。两性霉素治疗的中位持续时间为21(14-40)天。三十九名病人(68.4%)在治疗后出现低钾血症,27例(47.4%)患者出现低镁血症。共有34例(59.6%)患者在治疗时发生AKI。AKI发展的中位天数为6(4-10)天。基线中位数，最高和最终肌酐值为0.78（0.59-0.94）mg/dl，分别为1.27(0.89-2.16)mg/dl和0.93(0.74-1.59)mg/dl。从基线到最高值和最后随访值的中位数百分比变化分别为45％（0.43％-161％）和25％（-4.8％-90.1％）。36例（63.2%）患者的最终肌酐低于基线的150%。
UNASSIGNED：脱氧胆酸酯两性霉素是在资源有限的环境中治疗毛霉菌病的可接受的替代药物。
UNASSIGNED：这项从2019年至2021年的回顾性队列研究包括确诊的毛霉菌病患者，接受脱氧胆酸两性霉素B治疗超过或等于五天，并且在治疗中至少有三个肌酐值。基线人口统计详细信息，记录所有患者的危险因素和治疗细节.此外,我们确定了治疗相关不良反应和结局的详情.
未经批准：在纳入的57名患者中，有糖尿病史,COVID-19和类固醇的使用有49例（86%），43例（75.4%）和33例（57.9%）患者，分别。孤立的鼻-眶毛霉菌病是最常见的表现（n=49，86％）。中位随访时间为48（30.5-90）天。共有8名(14%)患者在住院期间死亡。两性霉素治疗的中位持续时间为21(14-40)天。三十九名病人(68.4%)在治疗后出现低钾血症,27例(47.4%)患者出现低镁血症。共有34例(59.6%)患者在治疗时发生AKI。AKI发展的中位天数为6(4-10)天。基线中位数，最高和最终肌酐值为0.78（0.59-0.94）mg/dl，分别为1.27(0.89-2.16)mg/dl和0.93(0.74-1.59)mg/dl。从基线到最高值和最后随访值的中位数百分比变化分别为45％（0.43％-161％）和25％（-4.8％-90.1％）。36例（63.2%）患者的最终肌酐低于基线的150%。
UNASSIGNED：脱氧胆酸酯两性霉素是在资源有限的环境中治疗毛霉菌病的可接受的替代药物。
